DELRAY BEACH, Fla., Feb. 07, 2017 -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that its E-N-G Mobile Systems (“ENG”) subsidiary, a mobile laboratory and specialty vehicle manufacturer, has received a purchase order for multiple mobile chemistry laboratories totaling more than $1.2 million. Due to the nature and location of the mobile labs, the customer is being kept confidential. This is the largest single order placed by a customer since PositiveID’s acquisition of ENG in December 2015.
The fastest growing segment of ENG's business over the last decade is its mobile labs, which include government and corporate laboratories for environmental, chemical, biological, nuclear, radiological and explosives testing in the field. ENG has delivered more than 400 MobiLabs to customers around the world, and has a team of scientists on staff who complement its design engineers to provide turnkey, customizable laboratories.
ENG has delivered more than 100 mobile labs for the U.S. Army, and numerous laboratories to other government agencies including U.S. Customs and Border Protection, U.S. Navy, U.S. Air Force, prominent national laboratories, and nine of the 10 regions of the Environmental Protection Agency.
“ENG is an industry leader in designing mobile labs to bring chemical and biological detection, monitoring, and analysis to the point of need where these capabilities are critical,” stated Lyle L. Probst, President of PositiveID. “We diligently pursued this significant order and we are proud that this important customer chose ENG to fulfill its needs.”
In addition to mobile labs, ENG has delivered more than 1,400 technical vehicle systems since its inception. These include communications/command centers, broadcast news vehicles, radio frequency monitoring, infrared monitoring and video communications vehicle systems, plus a wide range of mobile systems for emergency preparedness and threat response.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the specialty vehicle market, with a focus on mobile labs. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the specialty vehicle market; the Company’s ability to turn qualified pipeline opportunities into purchase orders; the possibility that a purchase order could be canceled; the Company’s ability to keep existing customers and attract new customers; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on November 18, 2016, August 12, 2016, and May 16, 2016, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contacts: PositiveID Corporation Allison Tomek (561) 805-8044 [email protected] RedChip Companies Jon Cunningham (407) 644-4256 [email protected]


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Italy Fines Apple €98.6 Million Over App Store Dominance
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 



